Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year indian review

Saarwaani Vallabhajosyula, Shashaank Vallabhajosyula, Saraschandra Vallabhajosyula, Suma Nair, Asha Kamath, Karthik N. Rao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Pioglitazone has better cardiovascular outcomes and a questionable relationship with bladder carcinoma in diabetes mellitus, type II (DM-2). We sought to evaluate the role of pioglitazone in the Indian population. Methods: This is a retrospective study at an academic medical center in India. All DM-2 patients in 2008 with a new prescription of pioglitazone were age- and gender-matched with non-users. We excluded patients with gestational DM or DM type I. They were followed forward for five years and demographic data, micro- and macro-vascular complications, mortality, and bladder carcinoma were recorded. Two-tailed p ≤ 0.05 was considered statistically significant. Results: Two cohorts of 260 patients, with mean age of 58±11 years with 413 (79.4%) males, were followed for five years. Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. HbA1cwas not different between groups. Over five years, pioglitazone users had lesser retinopathy and myocardial infarctions (all p < 0.01). Five cases of bladder carcinoma were noted, all in the pioglitazone group, however without statistical significance. Baseline variables, including mean daily pioglitazone dose, were not statistically different between patients with and without bladder carcinoma. Nephropathy and MI were independent predictors for development of bladder carcinoma within pioglitazone users. Conclusions: Pioglitazone users had significantly lesser myocardial infarctions and retinopathy despitemore difficult to control DM 2. In an age- and gender-matched cohort of users and nonusers, pioglitazone did not contribute to development of bladder cancer in the Indian population.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalMedical Journal Armed Forces India
Volume72
Issue number3
DOIs
Publication statusPublished - 01-07-2016

Fingerprint

pioglitazone
Blood Vessels
Urinary Bladder
Carcinoma
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Vallabhajosyula, Saarwaani ; Vallabhajosyula, Shashaank ; Vallabhajosyula, Saraschandra ; Nair, Suma ; Kamath, Asha ; Rao, Karthik N. / Development of vascular complications and bladder carcinoma in diabetics using pioglitazone : A five-year indian review. In: Medical Journal Armed Forces India. 2016 ; Vol. 72, No. 3. pp. 253-257.
@article{7217e5f75a96440f8a9338ff4a2f268f,
title = "Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year indian review",
abstract = "Background: Pioglitazone has better cardiovascular outcomes and a questionable relationship with bladder carcinoma in diabetes mellitus, type II (DM-2). We sought to evaluate the role of pioglitazone in the Indian population. Methods: This is a retrospective study at an academic medical center in India. All DM-2 patients in 2008 with a new prescription of pioglitazone were age- and gender-matched with non-users. We excluded patients with gestational DM or DM type I. They were followed forward for five years and demographic data, micro- and macro-vascular complications, mortality, and bladder carcinoma were recorded. Two-tailed p ≤ 0.05 was considered statistically significant. Results: Two cohorts of 260 patients, with mean age of 58±11 years with 413 (79.4{\%}) males, were followed for five years. Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. HbA1cwas not different between groups. Over five years, pioglitazone users had lesser retinopathy and myocardial infarctions (all p < 0.01). Five cases of bladder carcinoma were noted, all in the pioglitazone group, however without statistical significance. Baseline variables, including mean daily pioglitazone dose, were not statistically different between patients with and without bladder carcinoma. Nephropathy and MI were independent predictors for development of bladder carcinoma within pioglitazone users. Conclusions: Pioglitazone users had significantly lesser myocardial infarctions and retinopathy despitemore difficult to control DM 2. In an age- and gender-matched cohort of users and nonusers, pioglitazone did not contribute to development of bladder cancer in the Indian population.",
author = "Saarwaani Vallabhajosyula and Shashaank Vallabhajosyula and Saraschandra Vallabhajosyula and Suma Nair and Asha Kamath and Rao, {Karthik N.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.mjafi.2016.06.004",
language = "English",
volume = "72",
pages = "253--257",
journal = "Medical Journal Armed Forces India",
issn = "0377-1237",
publisher = "Medical Journal Armed Forces India",
number = "3",

}

Development of vascular complications and bladder carcinoma in diabetics using pioglitazone : A five-year indian review. / Vallabhajosyula, Saarwaani; Vallabhajosyula, Shashaank; Vallabhajosyula, Saraschandra; Nair, Suma; Kamath, Asha; Rao, Karthik N.

In: Medical Journal Armed Forces India, Vol. 72, No. 3, 01.07.2016, p. 253-257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of vascular complications and bladder carcinoma in diabetics using pioglitazone

T2 - A five-year indian review

AU - Vallabhajosyula, Saarwaani

AU - Vallabhajosyula, Shashaank

AU - Vallabhajosyula, Saraschandra

AU - Nair, Suma

AU - Kamath, Asha

AU - Rao, Karthik N.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Pioglitazone has better cardiovascular outcomes and a questionable relationship with bladder carcinoma in diabetes mellitus, type II (DM-2). We sought to evaluate the role of pioglitazone in the Indian population. Methods: This is a retrospective study at an academic medical center in India. All DM-2 patients in 2008 with a new prescription of pioglitazone were age- and gender-matched with non-users. We excluded patients with gestational DM or DM type I. They were followed forward for five years and demographic data, micro- and macro-vascular complications, mortality, and bladder carcinoma were recorded. Two-tailed p ≤ 0.05 was considered statistically significant. Results: Two cohorts of 260 patients, with mean age of 58±11 years with 413 (79.4%) males, were followed for five years. Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. HbA1cwas not different between groups. Over five years, pioglitazone users had lesser retinopathy and myocardial infarctions (all p < 0.01). Five cases of bladder carcinoma were noted, all in the pioglitazone group, however without statistical significance. Baseline variables, including mean daily pioglitazone dose, were not statistically different between patients with and without bladder carcinoma. Nephropathy and MI were independent predictors for development of bladder carcinoma within pioglitazone users. Conclusions: Pioglitazone users had significantly lesser myocardial infarctions and retinopathy despitemore difficult to control DM 2. In an age- and gender-matched cohort of users and nonusers, pioglitazone did not contribute to development of bladder cancer in the Indian population.

AB - Background: Pioglitazone has better cardiovascular outcomes and a questionable relationship with bladder carcinoma in diabetes mellitus, type II (DM-2). We sought to evaluate the role of pioglitazone in the Indian population. Methods: This is a retrospective study at an academic medical center in India. All DM-2 patients in 2008 with a new prescription of pioglitazone were age- and gender-matched with non-users. We excluded patients with gestational DM or DM type I. They were followed forward for five years and demographic data, micro- and macro-vascular complications, mortality, and bladder carcinoma were recorded. Two-tailed p ≤ 0.05 was considered statistically significant. Results: Two cohorts of 260 patients, with mean age of 58±11 years with 413 (79.4%) males, were followed for five years. Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. HbA1cwas not different between groups. Over five years, pioglitazone users had lesser retinopathy and myocardial infarctions (all p < 0.01). Five cases of bladder carcinoma were noted, all in the pioglitazone group, however without statistical significance. Baseline variables, including mean daily pioglitazone dose, were not statistically different between patients with and without bladder carcinoma. Nephropathy and MI were independent predictors for development of bladder carcinoma within pioglitazone users. Conclusions: Pioglitazone users had significantly lesser myocardial infarctions and retinopathy despitemore difficult to control DM 2. In an age- and gender-matched cohort of users and nonusers, pioglitazone did not contribute to development of bladder cancer in the Indian population.

UR - http://www.scopus.com/inward/record.url?scp=84983463261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983463261&partnerID=8YFLogxK

U2 - 10.1016/j.mjafi.2016.06.004

DO - 10.1016/j.mjafi.2016.06.004

M3 - Article

AN - SCOPUS:84983463261

VL - 72

SP - 253

EP - 257

JO - Medical Journal Armed Forces India

JF - Medical Journal Armed Forces India

SN - 0377-1237

IS - 3

ER -